http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 04 Mar 2026 12:45:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BICYCLE+THERAPEUTICS+++++++++++++++++++Filed+by%3A+WESTFIELD+CAPITAL+MANAGEMENT+CO+LP/26109540.html si-local-file:///var/storage/secattach/20260304/26109540.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BICYCLE+THERAPEUTICS+++++++++++++++++++Filed+by%3A+WESTFIELD+CAPITAL+MANAGEMENT+CO+LP/26109540.html Wed, 04 Mar 2026 12:45:00 -0500 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BICYCLE+THERAPEUTICS+++++++++++++++++++Filed+by%3A+WESTFIELD+CAPITAL+MANAGEMENT+CO+LP/26109540.html si-local-file:///var/storage/secattach/20260304/26109540.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BICYCLE+THERAPEUTICS+++++++++++++++++++Filed+by%3A+WESTFIELD+CAPITAL+MANAGEMENT+CO+LP/26109540.html Wed, 04 Mar 2026 12:45:00 -0500 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++BICYCLE+THERAPEUTICS+++++++++++++++++++Filed+by%3A+Invus+Global+Management%2C+LLC/26104210.html si-local-file:///var/storage/secattach/20260303/26104210.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++BICYCLE+THERAPEUTICS+++++++++++++++++++Filed+by%3A+Invus+Global+Management%2C+LLC/26104210.html Tue, 03 Mar 2026 17:40:00 -0500 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++BICYCLE+THERAPEUTICS+++++++++++++++++++Filed+by%3A+Invus+Global+Management%2C+LLC/26104210.html si-local-file:///var/storage/secattach/20260303/26104210.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++BICYCLE+THERAPEUTICS+++++++++++++++++++Filed+by%3A+Invus+Global+Management%2C+LLC/26104210.html Tue, 03 Mar 2026 17:40:00 -0500 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BICYCLE+THERAPEUTICS+++++++++++++++++++Filed+by%3A+WESTFIELD+CAPITAL+MANAGEMENT+CO+LP/26104014.html si-local-file:///var/storage/secattach/20260303/26104014.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BICYCLE+THERAPEUTICS+++++++++++++++++++Filed+by%3A+WESTFIELD+CAPITAL+MANAGEMENT+CO+LP/26104014.html Tue, 03 Mar 2026 17:28:00 -0500 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BICYCLE+THERAPEUTICS+++++++++++++++++++Filed+by%3A+WESTFIELD+CAPITAL+MANAGEMENT+CO+LP/26104014.html si-local-file:///var/storage/secattach/20260303/26104014.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BICYCLE+THERAPEUTICS+++++++++++++++++++Filed+by%3A+WESTFIELD+CAPITAL+MANAGEMENT+CO+LP/26104014.html Tue, 03 Mar 2026 17:28:00 -0500 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BICYCLE+THERAPEUTICS+++++++++++++++++++Filed+by%3A+WESTFIELD+CAPITAL+MANAGEMENT+CO+LP/26103937.html si-local-file:///var/storage/secattach/20260303/26103937.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BICYCLE+THERAPEUTICS+++++++++++++++++++Filed+by%3A+WESTFIELD+CAPITAL+MANAGEMENT+CO+LP/26103937.html Tue, 03 Mar 2026 17:25:00 -0500 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BICYCLE+THERAPEUTICS+++++++++++++++++++Filed+by%3A+WESTFIELD+CAPITAL+MANAGEMENT+CO+LP/26103937.html si-local-file:///var/storage/secattach/20260303/26103937.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BICYCLE+THERAPEUTICS+++++++++++++++++++Filed+by%3A+WESTFIELD+CAPITAL+MANAGEMENT+CO+LP/26103937.html Tue, 03 Mar 2026 17:25:00 -0500 BCYC O.36852577 http://www.streetinsider.com/Corporate+News/Seres+Therapeutics+names+Richard+Kender+as+interim+CEO/26091953.html <p>Seres Therapeutics (NASDAQ: MCRB) appointed Richard N. Kender as executive chair and interim chief executive officer, the company announced. Kender brings over 35 years of pharmaceutical industry experience, including his role as senior vice president of business development and corporate licensing at Merck & Co.</p><p>Kender has served on Seres' board of directors since September 2014. The previous co-CEOs, Tom DesRosier and Marella Thorell, will continue as chief legal officer and chief financial officer, respectively.</p><p>The Cambridge, Massachusetts-based biotechnology company is advancing live biotherapeutic programs focused on inflammatory and immune diseases. A clinical readout from an investigator-sponsored SER-155 study in immune checkpoint-related http://www.streetinsider.com/Corporate+News/Seres+Therapeutics+names+Richard+Kender+as+interim+CEO/26091953.html Mon, 02 Mar 2026 16:06:07 -0500 BCYC MCRB http://www.streetinsider.com/Corporate+News/Seres+Therapeutics+names+Richard+Kender+as+interim+CEO/26091953.html <p>Seres Therapeutics (NASDAQ: MCRB) appointed Richard N. Kender as executive chair and interim chief executive officer, the company announced. Kender brings over 35 years of pharmaceutical industry experience, including his role as senior vice president of business development and corporate licensing at Merck & Co.</p><p>Kender has served on Seres' board of directors since September 2014. The previous co-CEOs, Tom DesRosier and Marella Thorell, will continue as chief legal officer and chief financial officer, respectively.</p><p>The Cambridge, Massachusetts-based biotechnology company is advancing live biotherapeutic programs focused on inflammatory and immune diseases. A clinical readout from an investigator-sponsored SER-155 study in immune checkpoint-related http://www.streetinsider.com/Corporate+News/Seres+Therapeutics+names+Richard+Kender+as+interim+CEO/26091953.html Mon, 02 Mar 2026 16:06:07 -0500 BCYC MCRB http://www.streetinsider.com/Management+Changes/Seres+Therapeutics+names+Richard+Kender+as+interim+CEO/26091953.html <p>Seres Therapeutics (NASDAQ: MCRB) appointed Richard N. Kender as executive chair and interim chief executive officer, the company announced. Kender brings over 35 years of pharmaceutical industry experience, including his role as senior vice president of business development and corporate licensing at Merck & Co.</p><p>Kender has served on Seres' board of directors since September 2014. The previous co-CEOs, Tom DesRosier and Marella Thorell, will continue as chief legal officer and chief financial officer, respectively.</p><p>The Cambridge, Massachusetts-based biotechnology company is advancing live biotherapeutic programs focused on inflammatory and immune diseases. A clinical readout from an investigator-sponsored SER-155 study in immune checkpoint-related http://www.streetinsider.com/Management+Changes/Seres+Therapeutics+names+Richard+Kender+as+interim+CEO/26091953.html Mon, 02 Mar 2026 16:06:07 -0500 BCYC MCRB http://www.streetinsider.com/Management+Changes/Seres+Therapeutics+names+Richard+Kender+as+interim+CEO/26091953.html <p>Seres Therapeutics (NASDAQ: MCRB) appointed Richard N. Kender as executive chair and interim chief executive officer, the company announced. Kender brings over 35 years of pharmaceutical industry experience, including his role as senior vice president of business development and corporate licensing at Merck & Co.</p><p>Kender has served on Seres' board of directors since September 2014. The previous co-CEOs, Tom DesRosier and Marella Thorell, will continue as chief legal officer and chief financial officer, respectively.</p><p>The Cambridge, Massachusetts-based biotechnology company is advancing live biotherapeutic programs focused on inflammatory and immune diseases. A clinical readout from an investigator-sponsored SER-155 study in immune checkpoint-related http://www.streetinsider.com/Management+Changes/Seres+Therapeutics+names+Richard+Kender+as+interim+CEO/26091953.html Mon, 02 Mar 2026 16:06:07 -0500 BCYC MCRB http://www.streetinsider.com/Hot+Corp.+News/Seres+Therapeutics+names+Richard+Kender+as+interim+CEO/26091953.html <p>Seres Therapeutics (NASDAQ: MCRB) appointed Richard N. Kender as executive chair and interim chief executive officer, the company announced. Kender brings over 35 years of pharmaceutical industry experience, including his role as senior vice president of business development and corporate licensing at Merck & Co.</p><p>Kender has served on Seres' board of directors since September 2014. The previous co-CEOs, Tom DesRosier and Marella Thorell, will continue as chief legal officer and chief financial officer, respectively.</p><p>The Cambridge, Massachusetts-based biotechnology company is advancing live biotherapeutic programs focused on inflammatory and immune diseases. A clinical readout from an investigator-sponsored SER-155 study in immune checkpoint-related http://www.streetinsider.com/Hot+Corp.+News/Seres+Therapeutics+names+Richard+Kender+as+interim+CEO/26091953.html Mon, 02 Mar 2026 16:06:07 -0500 BCYC MCRB http://www.streetinsider.com/Hot+Corp.+News/Seres+Therapeutics+names+Richard+Kender+as+interim+CEO/26091953.html <p>Seres Therapeutics (NASDAQ: MCRB) appointed Richard N. Kender as executive chair and interim chief executive officer, the company announced. Kender brings over 35 years of pharmaceutical industry experience, including his role as senior vice president of business development and corporate licensing at Merck & Co.</p><p>Kender has served on Seres' board of directors since September 2014. The previous co-CEOs, Tom DesRosier and Marella Thorell, will continue as chief legal officer and chief financial officer, respectively.</p><p>The Cambridge, Massachusetts-based biotechnology company is advancing live biotherapeutic programs focused on inflammatory and immune diseases. A clinical readout from an investigator-sponsored SER-155 study in immune checkpoint-related http://www.streetinsider.com/Hot+Corp.+News/Seres+Therapeutics+names+Richard+Kender+as+interim+CEO/26091953.html Mon, 02 Mar 2026 16:06:07 -0500 BCYC MCRB http://www.streetinsider.com/Hot+Mgmt+Changes/Seres+Therapeutics+names+Richard+Kender+as+interim+CEO/26091953.html <p>Seres Therapeutics (NASDAQ: MCRB) appointed Richard N. Kender as executive chair and interim chief executive officer, the company announced. Kender brings over 35 years of pharmaceutical industry experience, including his role as senior vice president of business development and corporate licensing at Merck & Co.</p><p>Kender has served on Seres' board of directors since September 2014. The previous co-CEOs, Tom DesRosier and Marella Thorell, will continue as chief legal officer and chief financial officer, respectively.</p><p>The Cambridge, Massachusetts-based biotechnology company is advancing live biotherapeutic programs focused on inflammatory and immune diseases. A clinical readout from an investigator-sponsored SER-155 study in immune checkpoint-related http://www.streetinsider.com/Hot+Mgmt+Changes/Seres+Therapeutics+names+Richard+Kender+as+interim+CEO/26091953.html Mon, 02 Mar 2026 16:06:07 -0500 BCYC MCRB http://www.streetinsider.com/Hot+Mgmt+Changes/Seres+Therapeutics+names+Richard+Kender+as+interim+CEO/26091953.html <p>Seres Therapeutics (NASDAQ: MCRB) appointed Richard N. Kender as executive chair and interim chief executive officer, the company announced. Kender brings over 35 years of pharmaceutical industry experience, including his role as senior vice president of business development and corporate licensing at Merck & Co.</p><p>Kender has served on Seres' board of directors since September 2014. The previous co-CEOs, Tom DesRosier and Marella Thorell, will continue as chief legal officer and chief financial officer, respectively.</p><p>The Cambridge, Massachusetts-based biotechnology company is advancing live biotherapeutic programs focused on inflammatory and immune diseases. A clinical readout from an investigator-sponsored SER-155 study in immune checkpoint-related http://www.streetinsider.com/Hot+Mgmt+Changes/Seres+Therapeutics+names+Richard+Kender+as+interim+CEO/26091953.html Mon, 02 Mar 2026 16:06:07 -0500 BCYC MCRB http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html <p align="center"><em>Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience</em></p> <p align="center"><em>Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026</em></p> <p align="center"><em>SER-155 is Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes); efforts to secure funding for the program continue</em></p> <p align="center"><em>Company http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html Mon, 02 Mar 2026 16:05:00 -0500 A.00552549 A.08167664 A.32727947 A.50114197 A.50210872 A.50213784 BCYC MCRB O.00048394 O.00213680 O.08407916 O.09894302 O.23136602 O.36852577 O.45971719 O.51354437 http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html <p align="center"><em>Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience</em></p> <p align="center"><em>Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026</em></p> <p align="center"><em>SER-155 is Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes); efforts to secure funding for the program continue</em></p> <p align="center"><em>Company http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html Mon, 02 Mar 2026 16:05:00 -0500 A.00552549 A.08167664 A.32727947 A.50114197 A.50210872 A.50213784 BCYC MCRB O.00048394 O.00213680 O.08407916 O.09894302 O.23136602 O.36852577 O.45971719 O.51354437 http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html <p align="center"><em>Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience</em></p> <p align="center"><em>Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026</em></p> <p align="center"><em>SER-155 is Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes); efforts to secure funding for the program continue</em></p> <p align="center"><em>Company http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html Mon, 02 Mar 2026 16:05:00 -0500 A.00552549 A.08167664 A.32727947 A.50114197 A.50210872 A.50213784 BCYC MCRB O.00048394 O.00213680 O.08407916 O.09894302 O.23136602 O.36852577 O.45971719 O.51354437 http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html <p align="center"><em>Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience</em></p> <p align="center"><em>Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026</em></p> <p align="center"><em>SER-155 is Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes); efforts to secure funding for the program continue</em></p> <p align="center"><em>Company http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html Mon, 02 Mar 2026 16:05:00 -0500 A.00552549 A.08167664 A.32727947 A.50114197 A.50210872 A.50213784 BCYC MCRB O.00048394 O.00213680 O.08407916 O.09894302 O.23136602 O.36852577 O.45971719 O.51354437 http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html <p align="center"><em>Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience</em></p> <p align="center"><em>Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026</em></p> <p align="center"><em>SER-155 is Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes); efforts to secure funding for the program continue</em></p> <p align="center"><em>Company http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html Mon, 02 Mar 2026 16:05:00 -0500 A.00552549 A.08167664 A.32727947 A.50114197 A.50210872 A.50213784 BCYC MCRB O.00048394 O.00213680 O.08407916 O.09894302 O.23136602 O.36852577 O.45971719 O.51354437 http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html <p align="center"><em>Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience</em></p> <p align="center"><em>Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026</em></p> <p align="center"><em>SER-155 is Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes); efforts to secure funding for the program continue</em></p> <p align="center"><em>Company http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html Mon, 02 Mar 2026 16:05:00 -0500 A.00552549 A.08167664 A.32727947 A.50114197 A.50210872 A.50213784 BCYC MCRB O.00048394 O.00213680 O.08407916 O.09894302 O.23136602 O.36852577 O.45971719 O.51354437 http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html <p align="center"><em>Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience</em></p> <p align="center"><em>Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026</em></p> <p align="center"><em>SER-155 is Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes); efforts to secure funding for the program continue</em></p> <p align="center"><em>Company http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html Mon, 02 Mar 2026 16:05:00 -0500 A.00552549 A.08167664 A.32727947 A.50114197 A.50210872 A.50213784 BCYC MCRB O.00048394 O.00213680 O.08407916 O.09894302 O.23136602 O.36852577 O.45971719 O.51354437 http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html <p align="center"><em>Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience</em></p> <p align="center"><em>Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026</em></p> <p align="center"><em>SER-155 is Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes); efforts to secure funding for the program continue</em></p> <p align="center"><em>Company http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html Mon, 02 Mar 2026 16:05:00 -0500 A.00552549 A.08167664 A.32727947 A.50114197 A.50210872 A.50213784 BCYC MCRB O.00048394 O.00213680 O.08407916 O.09894302 O.23136602 O.36852577 O.45971719 O.51354437 http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html <p align="center"><em>Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience</em></p> <p align="center"><em>Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026</em></p> <p align="center"><em>SER-155 is Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes); efforts to secure funding for the program continue</em></p> <p align="center"><em>Company http://www.streetinsider.com/Press+Releases/Seres+Therapeutics+Announces+Appointment+of+Richard+N.+Kender+as+Executive+Chair+and+Interim+CEO%3B+Provides+Business+Updates/26091911.html Mon, 02 Mar 2026 16:05:00 -0500 A.00552549 A.08167664 A.32727947 A.50114197 A.50210872 A.50213784 BCYC MCRB O.00048394 O.00213680 O.08407916 O.09894302 O.23136602 O.36852577 O.45971719 O.51354437